Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DURTRE-RAD: Durvalumab +/- Tremelimumab with Radiotherapy in HNSCC
NCT03624231Phase 2Completed
- Start
- Aug 2018
- Primary completion
- Aug 2023
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in squamous cell carcinoma of the head and neck (HNSCC) comparing Durvalumab + Tremelimumab + RT with Durvalumab + RT (2 arms). Primary endpoints: Progression-Free Survival at 1 year and Treatment Discontinuation due to Toxicity. Started Aug 2018; status: completed.
02
Drugs
durvalumabtremelimumab
03
Conditions
squamous cell carcinoma of the head and neck (HNSCC)
Beyond the preview
Go deeper on NCT03624231.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03624231.